Board meeting on 3 November 2026 to approve unaudited Q2 and half-year results
Biogen Pharmachem Industries has told BSE its Board of Directors will meet on Tuesday 3 November 2026.
By ScoutQuest · · 1 min read
- Board Meeting Date
- Tuesday 3 November 2026
- Agenda Item
- Un-Audited Financial Results for the second quarter and half year ended 30 September 2026
- Notice Date
- 23.10.2026
What the company told the exchange
- Biogen Pharmachem Industries has intimated BSE that its Board of Directors will meet on Tuesday 3 November 2026.
- The main agenda item is to approve and take on record the Un-Audited Financial Results for the second quarter and half year ended 30 September 2026.
- The notice also lists a residual item: any other matter with the permission of the Board, which the Board may think fit.
- The letter is dated 23.10.2026 and is signed by a Director of the company.
Why this matters to a shareholder
The quarterly results are the regular scorecard a listed company publishes — revenue, expenses and profit for the three months and the six months gone by. A board meeting notice tells you the date on which those numbers are expected to be taken on record.
What this update does not do
It does not contain any financial figures. Nothing here tells you whether the quarter was good or weak. The results themselves, once approved by the Board, are what will carry the numbers.
- Treat this as a calendar marker: results for the September 2026 quarter are on the agenda for the 3 November 2026 meeting.
- The phrase "un-audited" is standard for quarterly results; a limited review by the auditors is the usual practice for such periods.
- The second agenda item is a routine enabling clause that lets the Board take up other business if needed.
What a reader can reasonably take away
The announcement is procedural in nature. It signals that the company is following its usual results calendar, and it sets a date on which investors will get the actual quarterly and half-yearly numbers.
Also from Biogen Pharmachem Industries
Biogen Pharmachem Industries Ltd shareholder sells 4.04% stake, holding falls to 00%
23 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.